186 related articles for article (PubMed ID: 22396166)
21. Phosphorus metabolism in chronic kidney disease.
Fourtounas C
Hippokratia; 2011 Jan; 15(Suppl 1):50-2. PubMed ID: 21897759
[TBL] [Abstract][Full Text] [Related]
22. FGF23 or PTH: which comes first in CKD ?
Isakova T; Wolf MS
Kidney Int; 2010 Nov; 78(10):947-9. PubMed ID: 21030968
[TBL] [Abstract][Full Text] [Related]
23. New insights into the FGF23-Klotho axis.
Olauson H; Vervloet MG; Cozzolino M; Massy ZA; Ureña Torres P; Larsson TE
Semin Nephrol; 2014 Nov; 34(6):586-97. PubMed ID: 25498378
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
Damasiewicz MJ; Toussaint ND; Polkinghorne KR
Nephrology (Carlton); 2011 Mar; 16(3):261-8. PubMed ID: 21265930
[TBL] [Abstract][Full Text] [Related]
25. Inflammation regulates fibroblast growth factor 23 production.
Francis C; David V
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):325-32. PubMed ID: 27191351
[TBL] [Abstract][Full Text] [Related]
26. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
[TBL] [Abstract][Full Text] [Related]
27. FGF23: a mature renal and cardiovascular risk factor?
Zoccali C; Yilmaz MI; Mallamaci F
Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
[TBL] [Abstract][Full Text] [Related]
28. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
29. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor 23/klotho axis in chronic kidney disease.
Nitta K; Nagano N; Tsuchiya K
Nephron Clin Pract; 2014; 128(1-2):1-10. PubMed ID: 25402964
[TBL] [Abstract][Full Text] [Related]
31. Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients.
Chathoth S; Al-Mueilo S; Cyrus C; Vatte C; Al-Nafaie A; Al-Ali R; Keating BJ; Al-Muhanna F; Al Ali A
Cardiorenal Med; 2015 Dec; 6(1):73-82. PubMed ID: 27194998
[TBL] [Abstract][Full Text] [Related]
32. 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism.
Barthel TK; Mathern DR; Whitfield GK; Haussler CA; Hopper HA; Hsieh JC; Slater SA; Hsieh G; Kaczmarska M; Jurutka PW; Kolek OI; Ghishan FK; Haussler MR
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):381-8. PubMed ID: 17293108
[TBL] [Abstract][Full Text] [Related]
33. Acute and long term mineral metabolism adaptation in living kidney donors: a prospective study.
Ponte B; Trombetti A; Hadaya K; Ernandez T; Fumeaux D; Iselin C; Martin PY; de Seigneux S
Bone; 2014 May; 62():36-42. PubMed ID: 24495507
[TBL] [Abstract][Full Text] [Related]
34. FGF23 and Klotho in chronic kidney disease.
Olauson H; Larsson TE
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
[TBL] [Abstract][Full Text] [Related]
35. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
36. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
Isakova T; Ix JH; Sprague SM; Raphael KL; Fried L; Gassman JJ; Raj D; Cheung AK; Kusek JW; Flessner MF; Wolf M; Block GA
J Am Soc Nephrol; 2015 Oct; 26(10):2328-39. PubMed ID: 25967123
[TBL] [Abstract][Full Text] [Related]
37. Caloric Intake in Renal Patients: Repercussions on Mineral Metabolism.
Vidal A; Ríos R; Pineda C; López I; Raya AI; Aguilera-Tejero E; Rodríguez M
Nutrients; 2020 Dec; 13(1):. PubMed ID: 33374582
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.
Saji F; Shigematsu T; Sakaguchi T; Ohya M; Orita H; Maeda Y; Ooura M; Mima T; Negi S
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1212-7. PubMed ID: 20739393
[TBL] [Abstract][Full Text] [Related]
39. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
Spichtig D; Zhang H; Mohebbi N; Pavik I; Petzold K; Stange G; Saleh L; Edenhofer I; Segerer S; Biber J; Jaeger P; Serra AL; Wagner CA
Kidney Int; 2014 Jun; 85(6):1340-50. PubMed ID: 24402093
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease.
Isakova T
Curr Opin Nephrol Hypertens; 2012 May; 21(3):334-40. PubMed ID: 22487610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
